CoChat

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Open access
Groisberg, Roman, Hong, David S., Behrang, Amini, Hess, Kenneth, Janku, Filip, Piha-Paul, Sarina, Naing, Aung, Fu, Siqing, Benjamin, Robert, Patel, Shreyaskumar, Somaiah, Neeta, Conley, Anthony, Meric-Bernstam, Funda, Subbiah, Vivek · 2017 · Journal for ImmunoTherapy of Cancer
Cited by 148

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. METHODS: We analyzed medical records of patients with advanced sarcoma who were referred to Phase 1 clinic at MD Anderson and received an immunotherapy (checkpoint inhibitors, vaccines, or cytokine based therapies). Clinical parameters including demographics, clinical history, toxicity, and response were abstracted. RESULTS: Among 50 patients enrolled in immunotherapy trials (Bone 10; Soft-tissue 40) we found 14 different subtypes of sarcomas. Royal Marsden Hospital (RMH) prognostic score was <2 (86%). Performance status (PS) was 0-1 in 48 patients (96%); median number of prior therapies was 3 (0-12). Immunotherapy consisted of checkpoint inhibitors (82%: PD1 = 7, PD-L1 = 11, CTLA4 = 22, other = 1) of which 42% were combinations, as well as vaccines (14%), and cytokines (4%). Median overall survival (OS) was 13.4 months (11.2 months: not reached). Median progression free survival (PFS) was 2.4 months (95% CI = 1.9-3.2 months). Best response was partial response (PR) in 2 patients with alveolar soft part sarcoma (ASPS) and stable disease (SD) in 11 patients (3 GIST, 3 liposarcomas (2 DDLS, 1 WDLS), 2 ASPS, 2 leiomyo, 1 osteo). PFS was 34% (23%, at 50%) at 3 months, 16% (8%, 30%) at 6 months, and 6% (2%, 20%) at 1 year. Pseudo-progression followed by stable disease was observed in 2 patients (4%). Grade 3/4 adverse events included rash (10%), fever (6%), fatigue (6%), and nausea/vomiting (6%). CONCLUSION: Immunotherapies were well tolerated in advanced sarcoma patients enrolled in trials. All four ASPS patients had clinical benefit with checkpoint inhibitors and this was the only subtype experiencing partial response. Further evaluation of checkpoint inhibitors in ASPS is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-017-0301-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 148

Metadata

Authors
Groisberg, R., Hong, D. S., Behrang, A., Hess, K., Janku, F., Piha-Paul, S., Naing, A., Fu, S., Benjamin, R., Patel, S., Somaiah, N., Conley, A., Meric-Bernstam, F., & Subbiah, V.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2017-12
Volume
5
Issue
1
Pages
100-100
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2773389902
Cited by
148
References
4
FWCI
9.92
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. https://app.cochat.ai/papers/10.1186/s40425-017-0301-y
The paper
Groisberg, R., Hong, D. S., Behrang, A., Hess, K., Janku, F., Piha-Paul, S., Naing, A., Fu, S., Benjamin, R., Patel, S., Somaiah, N., Conley, A., Meric-Bernstam, F., & Subbiah, V. (2017). Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-017-0301-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.